AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safe ...

Exelixis' future depends on trial outcomes and patent risks. Find out why EXEL stock is a "Sell" despite cabozantinib's ...

Facteus, the #1 provider of consumer transaction data and insights, today announced the release of Onyx, an untapped, industry-leading dataset of over $400B in annual consumer purchases across more ...

Discover the fascinating world of generational classifications! From the Silent Generation to Gen Z, each group has its own ...